Literature DB >> 26577601

Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administration in rats.

Guofei Li1, Fan Yang2, Mei Liu1, Xianying Su3, Mingming Zhao1, Limei Zhao1.   

Abstract

With the purpose of carrying out pharmacokinetic interaction studies ofnberberine (BBR) and fenofibrate (FBT), an UPLC-MS/MS method has been developed and validated. The analytes, BBR and fenofibric acid (FBA, metabolite of FBT) and the internal standard, tetrahydropalmatine, were extracted with dichloromethane-diethyl ether (3:2, v/v) and separated on an Agilent Eclipse XDB C18 column using a mobile phase composed of acetonitrile and water. With positive ion electrospray ionization, the analytes were monitored on a triple quadrupole mass spectrometer in multiple reaction monitoring mode. Linear calibration curves were obtained over the concentration ranges of 0.1-100.0 ng/mL for BBR and 10.0-50,000.0 ng/mL for FBA. For BBR and FBA, the intra- and inter-day precisions were <11.5 and 11.9%, respectively. The accuracy was within 11.7% and 11.3%. The mean recoveries of BBR at three concentrations of 0.2, 20.0, 80.0 ng/mL were >85.6%, and those of FBA at three concentrations of 20.0, 2500.0, 40,000.0 ng/mL were >87.9%. Consequently, the proposed method was applied to the pharmacokinetic interaction study of FBT combined with BBR after oral administration in rats and was proved to be sensitive, specific and reliable to analyze BBR and FBA in biological samples simultaneously.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  UPLC-MS/MS; berberine; drug-drug interaction; fenofibric acid; pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 26577601     DOI: 10.1002/bmc.3652

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  5 in total

1.  Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine.

Authors:  Beth Buchanan; Qingfang Meng; Mathieu-Marc Poulin; Jonathan Zuccolo; Chike Godwin Azike; Joseph Gabriele; David Charles Baranowski
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

2.  Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats.

Authors:  Yuzhen Jia; Binger Xu; Jisen Xu
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

3.  Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.

Authors:  Guofei Li; Mingming Zhao; Feng Qiu; Yaxin Sun; Limei Zhao
Journal:  Drug Des Devel Ther       Date:  2018-12-20       Impact factor: 4.162

4.  Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.

Authors:  Yingjie Qi; Guangxuan Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

5.  Toxicity and toxicokinetics of the ethanol extract of Zuojin formula.

Authors:  Shuo Wang; Tao Zhang; Xiaoyan Liu; Zheng Yang; Ludi Li; Danping Shan; Yadong Gao; Yingzi Li; Yanying Li; Youbo Zhang; Qi Wang
Journal:  BMC Complement Med Ther       Date:  2022-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.